Clinical trials: Respiratory Symptoms
Pulmonary Disease, Chronic Obstructive
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
The primary objective of this study is to compare the bronchodilator efficacy of three doses (50 µg, 100 µg and 200 µg) of BEA 2180 delivered by the Respimat® once daily to placebo and tiotropium bromide delivered by the…
- Trial name
- NCT00528996
- Testing
- BEA 2180 BR, Tiotropium Bromide
- Where
- 178 sites in United States, Canada and 8 more
- Volunteers
- 2,080 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2
After screening, subjects will enter a 4 week open-label run-in period with fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg administered once daily via dry powder inhaler (DPI).
- Trial name
- NCT02119286
- Testing
- FF, VI, UMEC
- Where
- 57 sites in United States, Czechia and 2 more
- Volunteers
- 620 people
- Sponsor
- GlaxoSmithKline
Hypoxia
Accuracy of Pulse Oximeters With Profound Hypoxia At Rest (NIHO17)
The aim of this study is to determine the accuracy of devices called pulse oximeters, which measure blood oxygen by shining light through fingers, ears or other skin, without requiring blood sampling.
- Trial name
- NCT05745662
- Testing
- Pulse Oximeter
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Nihon Kohden
Allergic Rhinitis
Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848
The primary purpose is to investigate tolerability/safety of repeated weekly doses of AZD8848 administered intranasally to seasonal allergic rhinitis patients.
- Trial name
- NCT00770003
- Testing
- AZD8848
- Where
- 2 sites in Sweden
- Volunteers
- 103 people
- Sponsor
- AstraZeneca
Sleep Disordered Breathing, Cheyne-Stokes Respiration
Feasibility Study to Determine the Effects of Phrenic Nerve Stimulation in Patients With Periodic Breathing
The purpose of this feasibility study is to determine the effect of stimulating the phrenic nerve to treat periodic breathing (a pattern of breathing characterized by hyperpneas followed by hypopneas or apneas).
- Conditions
- Sleep Disordered Breathing, Cheyne-Stokes Respiration, Sleep Apnea
- Trial name
- NCT00909259
- Testing
- Phrenic stimulation device
- Where
- 5 sites in United States, China and 1 more
- Volunteers
- 50 people
- Sponsor
- Respicardia, Inc.
Disease Progression
Treatment Resistance Following Anti-cancer Therapies
The TRANSLATE study aims to better understand why tumors become resistant to standard anti-cancer therapies. New tumor biopsy and blood samples are collected after disease progression on standard-of-care anti-cancer treatment and…
- Trial name
- NCT04436120
- Testing
- De novo tumor tissue biopsy, Research blood draws
- Where
- 33 sites in United States, Argentina and 3 more
- Volunteers
- 38 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer, NSCLC
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)
- Trial name
- NCT06917079
- Testing
- BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin)
- Where
- 17 sites in United States, Australia
- Volunteers
- 665 people
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Idiopathic Pulmonary Fibrosis
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.
- Trial name
- ELEVATE (NCT05321420)
- Testing
- Pirfenidone, Deupirfenidone
- Where
- 103 sites in United States, Argentina and 12 more
- Volunteers
- 240 people
- Sponsor
- PureTech
Asthma, Heart Failure
The General Breathing Record Study
This study will test the use of a new handheld device (called the N-Tidal C), that measures a person's tidal breath carbon dioxide, in diagnosing the cause of someone's breathlessness.
- Conditions
- Asthma, Heart Failure, Pneumonia, Motor Neuron Disease
- Trial name
- GBRS (NCT03356288)
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- TidalSense
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)
This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol.
- Trial name
- NCT01089127
- Testing
- Indacaterol, Salmeterol 50 μg
- Where
- 69 sites in United States
- Volunteers
- 552 people
- Sponsor
- Novartis Pharmaceuticals
SARS-CoV2 Infection
Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients
In COVID-19 infection caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a dysregulation of the immune system response that causes cytokine storm syndrome.
- Trial name
- EXOMSC-COV19 (NCT05216562)
- Testing
- Exosome-MSC Intravenous injection, COVID-19 Standard Treatment
- Where
- 3 sites in Indonesia
- Volunteers
- 60 people
- Sponsor
- Dermama Bioteknologi Laboratorium
Healthy Volunteer, URTI
LC-Plasma for Preventing URTIs and Reducing Symptoms
The goal of this study is to evaluate the efficacy of the LC-Plasma in preventing upper respiratory tract infections (URTIs) in healthy volunteers. Researchers will compare LC-Plasma to placebo to see if LC-Plasma prevents URTIs.
- Trial name
- NCT06827327
- Testing
- LC-Plasma
- Where
- Australia
- Volunteers
- 637 people, healthy volunteers welcome
- Sponsor
- RDC Clinical Pty Ltd
Refractory Chronic Cough
Treatment of Refractory Chronic Cough With PA101
This is a double-blind, randomized, placebo-controlled, 2-period crossover, 2-cohort study in adult patients with refractory chronic cough.
- Trial name
- NCT02412020
- Testing
- PA101
- Where
- 7 sites in Netherlands, United Kingdom
- Volunteers
- 52 people
- Sponsor
- Patara Pharma
Cough
Benzonatate Dose Tolerance Study
This is a single-center, randomized, third party blind, placebo controlled, dose escalation study of benzonatate following single dose administration.
- Trial name
- NCT01690975
- Testing
- Benzonatate - 400 mg, Benzonatate - 600 mg
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obstructive Sleep Apnea
Apnex Clinical Study of the Hypoglossal Nerve Stimulation (HGNS®) System to Treat Obstructive Sleep Apnea
The purpose of this study is to evaluate the benefits and risks of hypoglossal nerve stimulation with the Apnex Medical Hypoglossal Nerve Stimulation (HGNS) System as a potential therapeutic option for individuals with moderate…
- Trial name
- NCT01446601
- Testing
- Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )
- Where
- 14 sites in United States, Australia
- Volunteers
- 132 people
- Sponsor
- Apnex Medical, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD)
The purpose of the LINQ™ for COPD study is to characterize Reveal LINQ™ derived data from patients with COPD by assessing the relationship between changes in LINQ™ derived data with COPD exacerbation events.
- Trial name
- NCT04169529
- Testing
- Reveal LINQ
- Where
- 9 sites in United States
- Volunteers
- 42 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Pulmonary Disease, Chronic Obstructive
A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.
The primary objective of this study is to assess pharmacokinetics of tiotropium + olodaterol fixed-dose combination (2.5 µg/ 5 µg, 5 µg/ 5 µg) delivered by the RESPIMAT inhaler after 3 weeks once daily treatment in Japanese…
- Trial name
- NCT01703845
- Testing
- Tiotropium (high dose) + Olodaterol, Tiotropium (low dose) + Olodaterol
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
The prevalence, low cost, and low burden of wearable devices that provide quantitative and qualitative feedback on a subject's activity level present an opportunity for the use of these devices in clinical and observational…
- Trial name
- NCT02619357
- Testing
- SenseWear Armband Gecko, SenseWear Armband MF, Actigraph GT9x wristband and waistband
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease
Phase I study to evaluate the safety and tolerability of single ascending intravenous doses of MEDI2338 in subjects with stable, mild to moderate chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01322594
- Testing
- MEDI2338
- Where
- 4 sites in South Africa, United Kingdom
- Volunteers
- 31 people
- Sponsor
- MedImmune LLC
Healthy, Hypoxia
Prospective Study to Validate the Clinical Accuracy of the Norbert Device to Measure Oxygen Saturation
The purpose of this study is to evaluate the SpO2 accuracy and performance of the Norbert Device during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-oximetry for SpO2…
- Trial name
- NCT05685654
- Testing
- Norbert Device
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Norbert Health